The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization

Journal of Medicinal Chemistry

Volumn 60, Issue 9, 2017, Pages 3552-3579

  Pennington, Lewis D ^a   Moustakas, Demetri T ^a  

^a Alkermes   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CYTOCHROME P450; ELEMENT; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; LIM KINASE INHIBITOR; METABOTROPIC RECEPTOR 4; NALOXONE; NALTREXONE; NEPLANOCIN A; NITROGEN; PREGNANE X RECEPTOR; PROTEIN KINASE SYK INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALLOSTERISM; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ATOM; BINDING SITE; CELL MEMBRANE PERMEABILITY; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG BINDING; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; HUMAN; IC50; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; METABOLIC STABILITY; MOLECULAR DOCKING; MULTIPARAMETER OPTIMIZATION; NONHUMAN; PHARMACOKINETIC PARAMETERS; PHARMACOLOGICAL PARAMETERS; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; REVIEW; STRUCTURE ACTIVITY RELATION; CHEMISTRY;

BINDING SITES; DRUG DESIGN; NITROGEN;

EID: 85019254552     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01807     Document Type: Review

References (139)

1. Raviña, E. The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2011; pp 1-22.
2. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25 10.1016/S0169-409X(96)00423-1
3. Garbaccio, R. M.; Parmee, E. R. The impact of chemical probes in drug discovery: a pharmaceutical industry perspective Cell Chem. Biol. 2016, 23, 10-16 10.1016/j.chembiol.2015.11.011
4. Arrowsmith, C. H.; Audia, J. E.; Austin, C.; Baell, J.; Bennett, J.; Blagg, J.; Bountra, C.; Brennan, P. E.; Brown, P. J.; Bunnage, M. E.; Buser-Doepner, C.; Campbell, R. M.; Carter, A. J.; Cohen, P.; Copeland, R. A.; Cravatt, B.; Dahlin, J. L.; Dhanak, D.; Edwards, A. M.; Frederiksen, M.; Frye, S. V.; Gray, N.; Grimshaw, C. E.; Hepworth, D.; Howe, T.; Huber, K. V. M; Jin, J.; Knapp, S.; Kotz, J. D.; Kruger, R. G.; Lowe, D.; Mader, M. M.; Marsden, B.; Mueller-Fahrnow, A.; Müller, S.; O’Hagan, R. C.; Overington, J. P.; Owen, D. R.; Rosenberg, S. H.; Ross, R.; Roth, B.; Schapira, M.; Schreiber, S. L.; Shoichet, B.; Sundström, M.; Superti-Furga, G.; Taunton, J.; Toledo-Sherman, L.; Walpole, C.; Walters, M. A.; Willson, T. M.; Workman, P.; Young, R. N.; Zuercher, W. J. The promise and peril of chemical probes Nat. Chem. Biol. 2015, 11, 536-541 10.1038/nchembio.1867
5. Paul, S. M.; Mytelka, D. S.; Dunwiddie, C. T.; Persinger, C. C.; Munos, B. H.; Lindborg, S. R.; Schacht, A. L. How to improve R&D productivity: the pharmaceutical industry’s grand challenge Nat. Rev. Drug Discovery 2010, 9, 203-214 10.1038/nrd3078
6. Segall, M. D. Multi-parameter optimization: identifying high quality compounds with a balance of properties Curr. Pharm. Des. 2012, 18, 1292-1310 10.2174/138161212799436430
7. Sutherland, J. J.; Raymond, J. W.; Stevens, J. L.; Baker, T. K.; Watson, D. E. Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes J. Med. Chem. 2012, 55, 6455-6466 10.1021/jm300684u
8. Meanwell, N. A. Improving drug candidates by design: focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 2011, 24, 1420-1456 10.1021/tx200211v
9. Cumming, J. G.; Davis, A. M.; Muresan, S.; Haeberlein, M.; Chen, H. Chemical predictive modeling to improve compound quality Nat. Rev. Drug Discovery 2013, 12, 948-962 10.1038/nrd4128
10. Kuhn, B.; Guba, W.; Hert, J.; Banner, D. W.; Bissantz, C.; Ceccarelli, S. M.; Haap, W.; Körner, M.; Kuglstatter, A.; Lerner, C. D.; Mattei, P.; Neidhart, W.; Pinard, E.; Rudolph, M. G.; Schulz-Gasch, T.; Woltering, T. J.; Stahl, M. A real-world perspective on molecular design J. Med. Chem. 2016, 59, 4087-4102 10.1021/acs.jmedchem.5b01875
11. Segall, M. D.; Yusof, I.; Champness, E. J. Avoiding missed opportunities by analyzing the sensitivity of our decisions J. Med. Chem. 2016, 59, 4267-4277 10.1021/acs.jmedchem.5b01921
12. Schönherr, H.; Cernak, T. Profound methyl effects in drug discovery and a call for new C-H methylation reactions Angew. Chem., Int. Ed. 2013, 52, 12256-12267 10.1002/anie.201303207
13. Leung, C. S.; Leung, S. S. F.; Tirado-Rives, J.; Jorgensen, W. L. Methyl effects on protein-ligand binding J. Med. Chem. 2012, 55, 4489-4500 10.1021/jm3003697
14. Bryan, M. C.; Falsey, J. R.; Frohn, M.; Reichelt, A.; Yao, G.; Bartberger, M. D.; Bailis, J. M.; Zalameda, L.; San Miguel, T.; Doherty, E. M.; Allen, J. G. N-Substituted azaindoles as potent inhibitors of Cdc7 kinase Bioorg. Med. Chem. Lett. 2013, 23, 2056-2060 10.1016/j.bmcl.2013.02.007
15. Pennington, L. D. Molecular design in ligand-and structure-based drug discovery. Presented at the University of Michigan Department of Chemistry Seminar Series; University of Michigan: Ann Arbor, MI, November 25, 2014.
16. 1. Presented at the Overman Symposium; Eli Lilly & Co.: Indianapolis, IN, September 12, 2013.
17. Meanwell, N. A. Synopsis of some recent tactical application of bioisosteres in drug design J. Med. Chem. 2011, 54, 2529-2591 10.1021/jm1013693
18. Bioisosteres in Medicinal Chemistry; Brown, N., Ed.; Methods and Principles in Medicinal Chemistry; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2012; Vol 54.
19. Meanwell, N. A. The influence of bioisosteres in drug design: tactical applications to address developability problems Top. Med. Chem. 2015, 9, 283-382 10.1007/7355_2013_29
20. Jacobi, P. A. Principles of heterocyclic chemistry. Presented at Amgen, Inc.: Thousand Oaks, CA, May 8-9, 2006.
21. Bondi, A. van der Waals volumes and radii J. Phys. Chem. 1964, 68, 441-451 10.1021/j100785a001
22. Nobeli, I.; Price, S. L.; Lommerse, J. P. M.; Taylor, R. Hydrogen bonding properties of oxygen and nitrogen acceptors in aromatic heterocycles J. Comput. Chem. 1997, 18, 2060-2074 10.1002/(SICI)1096-987X(199712)18:16<2060::AID-JCC10>3.0.CO;2-S
23. BHX database: toward a better understanding of hydrogen-bond basicity for medicinal chemists J. Med. Chem. 2009, 52, 4073-4086 10.1021/jm801331y
24. Kenny, P. W.; Montanari, C. A.; Prokopczyk, I. M.; Ribeiro, J. F. R.; Sartori, G. R. Hydrogen bond basicity prediction for medicinal chemistry design J. Med. Chem. 2016, 59, 4278-4288 10.1021/acs.jmedchem.5b01946
25. Eicher, T.; Hauptmann, S.; Speicher, A. The Chemistry of Heterocycles: Structures, Reactions, Synthesis, and Applications, 3rd ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2012.
26. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties J. Med. Chem. 2000, 43, 3714-3717 10.1021/jm000942e
27. Calculated log P (CLogP) values were obtained using ChemDraw Professional Software, version 15.0; PerkinElmer, Inc.: 940 Winter Street, Waltham, MA 02451.
28. Arnold, D. S.; Plank, C. A.; Erickson, E. E.; Pike, F. P. Solubility of benzene in water Chem. Eng. Data Ser. 1958, 3, 253-256 10.1021/i460004a016
29. Arimura, M.; Yoshikawa, Y. Ionization efficiency and ionization energy of cyclic compounds by electron impact J. Mass Spectrom. Soc. Jpn. 1984, 32, 375-380 10.5702/massspec.32.375
30. The electrostatic potential maps were generated using Spartan ’14 Software, version 1.1.8; Wavefunction, Inc.: 18401 Von Karman Avenue, Suite 370, Irvine, CA 92612.
31. Hohenstein, E. G.; Sherrill, C. D. Effects of heteroatoms on aromatic π-π interactions: benzene-pyridine and pyridine dimer J. Phys. Chem. A 2009, 113, 878-886 10.1021/jp809062x
32. Huber, R. G.; Margreiter, M. A.; Fuchs, J. E.; von Grafenstein, S.; Tautermann, C. S.; Liedl, K. R.; Fox, T. Heteroaromatic π-stacking energy landscapes J. Chem. Inf. Model. 2014, 54, 1371-1379 10.1021/ci500183u
33. Mecozzi, S.; West, A. P., Jr.; Dougherty, D. A. Cation−π interactions in simple aromatics: electrostatics provide a predictive tool J. Am. Chem. Soc. 1996, 118, 2307-2308 10.1021/ja9539608
34. Mecozzi, S.; West, A. P., Jr.; Dougherty, D. A. Cation−π interactions in aromatics of biological and medicinal interest: electrostatic potential surfaces as a useful qualitative guide Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 10566-10571 10.1073/pnas.93.20.10566
35. Desiraju, G. R.; Steiner, T. The Weak Hydrogen Bond in Structural Chemistry and Biology; Oxford University Press: Oxford, 1999.
36. Bradamante, S.; Pagani, G. A. Benzyl and heteroarylmethyl carbanions: structure and substituent effects. In Advances in Carbanion Chemistry; Snieckus, V., Ed.; JAI: New York, 1996; Vol. 2, pp 189-263.
37. St. Jean, D. J., Jr.; Fotsch, C. Mitigating heterocycle metabolism in drug discovery J. Med. Chem. 2012, 55, 6002-6020 10.1021/jm300343m
38. Beno, B. R.; Yeung, K.-S.; Bartberger, M. D.; Pennington, L. D.; Meanwell, N. A. A survey of the role of noncovalent sulfur interactions in drug design J. Med. Chem. 2015, 58, 4383-4438 10.1021/jm501853m
39. Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemist’s guide to molecular interactions J. Med. Chem. 2010, 53, 5061-5084 10.1021/jm100112j
40. Hitchcock, S. A. Structure modifications that alter the P-glycoprotein efflux properties of compounds J. Med. Chem. 2012, 55, 4877-4895 10.1021/jm201136z
41. Desai, P. V.; Raub, T. J.; Blanco, M.-J. How hydrogen bonds impact P-glycoprotein transport and permeability Bioorg. Med. Chem. Lett. 2012, 22, 6540-6548 10.1016/j.bmcl.2012.08.059
42. Leach, A. G. Tactics to avoid inhibition of cytochrome P450s Top. Med. Chem. 2015, 9, 107-158 10.1007/7355_2013_25
43. Sinz, M. W. Avoiding PXR and CAR activation and CYP3A4 enzyme induction Top. Med. Chem. 2015, 9, 159-190 10.1007/7355_2013_24
44. Leishman, K. J.; Rankovic, Z. Drug discovery versus hERG Top. Med. Chem. 2015, 9, 225-260 10.1007/7355_2014_38
45. 1: use of a N-scan SAR strategy to optimize in vitro and in vivo activity Bioorg. Med. Chem. Lett. 2012, 22, 527-531 10.1016/j.bmcl.2011.10.085
46. Hajduk, P. J.; Sauer, D. R. Statistical analysis of the effects of common chemical substituents on ligand potency J. Med. Chem. 2008, 51, 553-564 10.1021/jm070838y
47. Dimova, D.; Stumpfe, D.; Bajorath, J. Specific chemical changes leading to consistent potency increases in structurally diverse active compounds MedChemComm 2014, 5, 742-749 10.1039/c4md00029c
48. Wassermann, A. M.; Bajorath, J. Chemical substitutions that introduce activity cliffs across different compound classes and biological targets J. Chem. Inf. Model. 2010, 50, 1248-1256 10.1021/ci1001845
49. Wassermann, A. M.; Bajorath, J. Large-scale exploration of bioisosteric replacements on the basis of matched molecular pairs Future Med. Chem. 2011, 3, 425-436 10.4155/fmc.10.293
50. Keefer, C. E.; Chang, G.; Kauffman, G. W. Extraction of tacit knowledge from large ADME data sets via pairwise analysis Bioorg. Med. Chem. 2011, 19, 3739-3749 10.1016/j.bmc.2011.05.003
51. Chang, G.; Huard, K.; Kauffman, G. W.; Stepan, A. F.; Keefer, C. E. A multi-endpoint matched molecular pair (MMP) analysis of 6-membered heterocycles Bioorg. Med. Chem. 2017, 25, 381-388 10.1016/j.bmc.2016.11.004
52. Kramer, C.; Fuchs, J. E.; Whitebread, S.; Gedeck, P.; Liedl, K. R. Matched molecular pair analysis: significance and the impact of experimental uncertainty J. Med. Chem. 2014, 57, 3786-3802 10.1021/jm500317a
53. Hu, Y.; de la Vega de León, A.; Zhang, B.; Bajorath, J. Matched molecular pair-based data sets for computer-aided medicinal chemistry F1000Research 2014, 10.12688/f1000research.3-36.v1
54. Hu, Y.; de la Vega de León, A.; Zhang, B.; Bajorath, J. Data sets of MMP-cliffs, SAR transfer series and RECAP-MMPs Zenodo 2014, 10.5281/zenodo.7750
55. de la Vega de León, A.; Bajorath, J. Matched molecular pairs derived by retrosynthetic fragmentation MedChemComm 2014, 5, 64-67 10.1039/C3MD00259D
56. Chuprina, A.; Lukin, O.; Demoiseaux, R.; Buzko, A.; Shivanyuk, A. Drug-and lead-likeness, target class, and molecular diversity analysis of 7.9 million commercially available organic compounds provided by 29 suppliers J. Chem. Inf. Model. 2010, 50, 470-479 10.1021/ci900464s
57. Nadin, A.; Hattotuwagama, C.; Churcher, I. Lead-oriented synthesis: a new opportunity for synthetic chemistry Angew. Chem., Int. Ed. 2012, 51, 1114-1122 10.1002/anie.201105840
58. Perola, E. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs J. Med. Chem. 2010, 53, 2986-2997 10.1021/jm100118x
59. Leach, A. G.; Kidley, N. J. Quantitatively interpreted enhanced inhibition of cytochrome P450s by heteroaromatic rings containing nitrogen J. Chem. Inf. Model. 2011, 51, 1048-1063 10.1021/ci2000506
60. Ritchie, T. J.; Macdonald, S. J. F.; Peace, S.; Pickett, S. D.; Luscombe, C. N. The developability of heteroaromatic and heteroaliphatic rings-do some have a better pedigree as potential drug molecules than others? MedChemComm 2012, 3, 1062-1069 10.1039/c2md20111a
61. Sanoh, S.; Tayama, Y.; Sugihara, K.; Kitamura, S.; Ohta, S. Significance of aldehyde oxidase during drug development: effects on drug metabolism, pharmacokinetics, toxicity, and efficacy Drug Metab. Pharmacokinet. 2015, 30, 52-63 10.1016/j.dmpk.2014.10.009
62. Hutzler, J. M.; Obach, R. S.; Dalvie, D.; Zientek, M. A. Strategies for a comprehensive understanding of metabolism by aldehyde oxidase Expert Opin. Drug Metab. Toxicol. 2013, 9, 153-168 10.1517/17425255.2013.738668
63. Vitaku, E.; Smith, D. T.; Njardarson, J. T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals J. Med. Chem. 2014, 57, 10257-10274 10.1021/jm501100b
64. Taylor, R. D.; MacCoss, M.; Lawson, A. D. G. Rings in drugs J. Med. Chem. 2014, 57, 5845-5859 10.1021/jm4017625
65. Charifson, P. S.; Walters, W. P. Acidic and basic drugs in medicinal chemistry: a perspective J. Med. Chem. 2014, 57, 9701-9717 10.1021/jm501000a
66. Abraham, M. H.; Whiting, G. S.; Fuchs, R.; Chambers, E. J. Thermodynamics of solute transfer from water to hexadecane J. Chem. Soc., Perkin Trans. 2 1990, 1990, 291-300 10.1039/p29900000291
67. Michel, J.; Tirado-Rives, J.; Jorgensen, W. L. J. Energetics of displacing water molecules from protein binding sites: consequences for lead optimization J. Am. Chem. Soc. 2009, 131, 15403-15411 10.1021/ja906058w
68. 3 receptor ligands J. Med. Chem. 2012, 55, 8603-8614 10.1021/jm300801u
69. 3 receptor Nature 2014, 512, 276-281 10.1038/nature13552
70. Borrmann, T.; Abdelrahman, A.; Volpini, R.; Lambertucci, C.; Alksnis, E.; Gorzalka, S.; Knospe, M.; Schiedel, A. C.; Cristalli, G.; Müller, C. E. Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family J. Med. Chem. 2009, 52, 5974-5989 10.1021/jm9006356
71. Siddiqi, S. M.; Jacobson, K. A.; Esker, J. L.; Olah, M. E.; Ji, X.-D.; Melman, N.; Tiwari, K. N.; Secrist, J. A., III; Schneller, S. W.; Cristalli, G.; Stiles, G. L.; Johnson, C. R.; IJzerman, A. P. Search for new purine-and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors J. Med. Chem. 1995, 38, 1174-1188 10.1021/jm00007a014
72. Chandra, G.; Moon, Y. W.; Lee, Y.; Jang, J. Y.; Song, J.; Nayak, A.; Oh, K.; Mulamoottil, V. A.; Sahu, P. K.; Kim, G.; Chang, T.-S.; Noh, M.; Lee, S. K.; Choi, S.; Jeong, L. S. Structure-activity relationships of neplanocin A analogues as S-adenosylhomocysteine hydrolase inhibitors and their antiviral and antitumor activities J. Med. Chem. 2015, 58, 5108-5120 10.1021/acs.jmedchem.5b00553
73. Yuan, Y.; Zaidi, S. A.; Elbegdorj, O.; Aschenbach, L. C. K.; Li, G.; Stevens, D. L.; Scoggins, K. L.; Dewey, W. L.; Selley, D. E.; Zhang, Y. Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity J. Med. Chem. 2013, 56, 9156-9169 10.1021/jm4012214
74. S-X) interaction for conformational constraint J. Med. Chem. 2015, 58, 9663-9679 10.1021/acs.jmedchem.5b01367
75. Lawhorn, B. G.; Philp, J.; Zhao, Y.; Louer, C.; Hammond, M.; Cheung, M.; Fries, H.; Graves, A. P.; Shewchuk, L.; Wang, L.; Cottom, J. E.; Qi, H.; Zhao, H.; Totoritis, R.; Zhang, G.; Schwartz, B.; Li, H.; Sweitzer, S.; Holt, D. A.; Gatto, G. J., Jr.; Kallander, L. S. Identification of purines and 7-deazapurines as potent and selective type I inhibitors of troponin I-interacting kinase (TNNI3K) J. Med. Chem. 2015, 58, 7431-7448 10.1021/acs.jmedchem.5b00931
76. Verhoest, P. R.; Chapin, D. S.; Corman, M.; Fonseca, K.; Harms, J. F.; Hou, X.; Marr, E. S.; Menniti, F. S.; Nelson, F.; O’Connor, R.; Pandit, J.; Proulx-LaFrance, C.; Schmidt, A. W.; Schmidt, C. J.; Suiciak, J. A.; Liras, S. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia J. Med. Chem. 2009, 52, 5188-5196 10.1021/jm900521k
77. Vanotti, E.; Amici, R.; Bargiotti, A.; Berthelsen, J.; Bosotti, R.; Ciavolella, A.; Cirla, A.; Cristiani, C.; D’Alessio, R.; Forte, B.; Isacchi, A.; Martina, K.; Menichincheri, M.; Molinari, A.; Montagnoli, A.; Orsini, P.; Pillan, A.; Roletto, F.; Scolaro, A.; Tibolla, M.; Valsasina, B.; Varasi, M.; Volpi, D.; Santocanale, C. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships J. Med. Chem. 2008, 51, 487-501 10.1021/jm700956r
78. Pierre, F.; Chua, P. C.; O’Brien, S. E.; Siddiqui-Jain, A.; Bourbon, P.; Haddach, M.; Michaux, J.; Nagasawa, J.; Schwaebe, M. K.; Stefan, E.; Vialettes, A.; Whitten, J. P.; Chen, T. K.; Darjania, L.; Stansfield, R.; Anderes, K.; Bliesath, J.; Drygin, D.; Ho, C.; Omori, M.; Proffitt, C.; Streiner, N.; Trent, K.; Rice, W. G.; Ryckman, D. M. Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer J. Med. Chem. 2011, 54, 635-654 10.1021/jm101251q
79. Ellis, J. M.; Altman, M. D.; Bass, A.; Butcher, J. W.; Byford, A. J.; Donofrio, A.; Galloway, S.; Haidle, A. M.; Jewell, J.; Kelly, N.; Leccese, E. K.; Lee, S.; Maddess, M.; Miller, J. R.; Moy, L. Y.; Osimboni, E.; Otte, R. D.; Reddy, M. V.; Spencer, K.; Sun, B.; Vincent, S. H.; Ward, G. J.; Woo, G. H. C.; Yang, C.; Houshyar, H.; Northrup, A. B. Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors J. Med. Chem. 2015, 58, 1929-1939 10.1021/jm5018169
80. D’Angelo, N. D.; Kim, T.-S.; Andrews, K.; Booker, S. K.; Caenepeel, S.; Chen, K.; D’Amico, D.; Freeman, D.; Jiang, J.; Liu, L.; McCarter, J. D.; San Miguel, T.; Mullady, E. L.; Schrag, M.; Subramanian, R.; Tang, J.; Wahl, R. C.; Wang, L.; Whittington, D. A.; Wu, T.; Xi, N.; Xu, Y.; Yakowec, P.; Yang, K.; Zalameda, L. P.; Zhang, N.; Hughes, P.; Norman, M. H. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors J. Med. Chem. 2011, 54, 1789-1811 10.1021/jm1014605
81. Duraiswamy, A. J.; Lee, M. A.; Madan, B.; Ang, S. H.; Tan, E. S. W.; Cheong, W. W. V.; Ke, Z.; Pendharkar, V.; Ding, L. J.; Chew, Y. S.; Manoharan, V.; Sangthongpitag, K.; Alam, J.; Poulsen, A.; Ho, S. Y.; Virshup, D. M.; Keller, T. H. Discovery and optimization of a porcupine inhibitor J. Med. Chem. 2015, 58, 5889-5899 10.1021/acs.jmedchem.5b00507
82. Blum, C. A.; Caldwell, T.; Zheng, X.; Bakthavatchalam, R.; Capitosti, S.; Brielmann, H.; De Lombaert, S.; Kershaw, M. T.; Matson, D.; Krause, J. E.; Cortright, D.; Crandall, M.; Martin, W. J.; Murphy, B. A.; Boyce, S.; Jones, A. B.; Mason, G.; Rycroft, W.; Perrett, H.; Conley, R.; Burnaby-Davies, N.; Chenard, B. L.; Hodgetts, K. J. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists J. Med. Chem. 2010, 53, 3330-3348 10.1021/jm100051g
83. Dandapani, S.; Germain, A. R.; Jewett, I.; le Quement, S.; Marie, J.-C.; Muncipinto, G.; Duvall, J. R.; Carmody, L. C.; Perez, J. R.; Engel, J. C.; Gut, J.; Kellar, D.; Siqueira-Neto, J. L.; McKerrow, J. H.; Kaiser, M.; Rodriguez, A.; Palmer, M. A.; Foley, M.; Schreiber, S. L.; Munoz, B. Diversity-oriented synthesis yields a new drug lead for treatment of Chagas disease ACS Med. Chem. Lett. 2014, 5, 149-153 10.1021/ml400403u
84. Zhao, B.; Li, Y.; Xu, P.; Dai, Y.; Luo, C.; Sun, Y.; Ai, J.; Geng, M.; Duan, W. Discovery of substituted 1H-pyrazolo[3,4-b]pyridine derivatives as potent and selective FGFR kinase inhibitors ACS Med. Chem. Lett. 2016, 7, 629-634 10.1021/acsmedchemlett.6b00066
85. Fox, B. M.; Beck, H. P.; Roveto, P. M.; Kayser, F.; Cheng, Q.; Dou, H.; Williamson, T.; Treanor, J.; Liu, H.; Jin, L.; Xu, G.; Ma, J.; Wang, S.; Olson, S. H. A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques J. Med. Chem. 2015, 58, 5256-5273 10.1021/acs.jmedchem.5b00567
86. Yin, Y.; Zheng, K.; Eid, N.; Howard, S.; Jeong, J.-H.; Yi, F.; Guo, J.; Park, C. M.; Bibian, M.; Wu, W.; Hernandez, P.; Park, H.; Wu, Y.; Luo, J.-L.; LoGrasso, P. V.; Feng, Y. Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors J. Med. Chem. 2015, 58, 1846-1861 10.1021/jm501680m
87. Li, Z.; Wang, X.; Eksterowicz, J.; Gribble, M. W., Jr.; Alba, G. Q.; Ayres, M.; Carlson, T. J.; Chen, A.; Chen, X.; Cho, R.; Connors, R. V.; DeGraffenreid, M.; Deignan, J. T.; Duquette, J.; Fan, P.; Fisher, B.; Fu, J.; Huard, J. N.; Kaizerman, J.; Keegan, K. S.; Li, C.; Li, K.; Li, Y.; Liang, L.; Liu, W.; Lively, S. E.; Lo, M.-C.; Ma, J.; McMinn, D. L.; Mihalic, J. T.; Modi, K.; Ngo, R.; Pattabiraman, K.; Piper, D. E.; Queva, C.; Ragains, M. L.; Suchomel, J.; Thibault, S.; Walker, N.; Wang, X.; Wang, Z.; Wanska, M.; Wehn, P. M.; Weidner, M. F.; Zhang, A. J.; Zhao, X.; Kamb, A.; Wickramasinghe, D.; Dai, K.; McGee, L. R.; Medina, J. C. Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3 J. Med. Chem. 2014, 57, 3430-3449 10.1021/jm500118j
88. Henry, J. R.; Kaufman, M. D.; Peng, S.-B.; Ahn, Y. M.; Caldwell, T. M.; Vogeti, L.; Telikepalli, H.; Lu, W.-P.; Hood, M. M.; Rutkoski, T. J.; Smith, B. D.; Vogeti, S.; Miller, D.; Wise, S. C.; Chun, L.; Zhang, X.; Zhang, Y.; Kays, L.; Hipskind, P. A.; Wrobleski, A. D.; Lobb, K. L.; Clay, J. M.; Cohen, J. D.; Walgren, J. L.; McCann, D.; Patel, P.; Clawson, D. K.; Guo, S.; Manglicmot, D.; Groshong, C.; Logan, C.; Starling, J. J.; Flynn, D. L. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells J. Med. Chem. 2015, 58, 4165-4179 10.1021/acs.jmedchem.5b00067
89. Morales, G. A.; Garlich, J. R.; Su, J.; Peng, X.; Newblom, J.; Weber, K.; Durden, D. L. Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors J. Med. Chem. 2013, 56, 1922-1939 10.1021/jm301522m
90. O’Donnell, C. J.; Rogers, B. N.; Bronk, B. S.; Bryce, D. K.; Coe, J. W.; Cook, K. K.; Duplantier, A. J.; Evrard, E.; Hajós, M.; Hoffmann, W. E.; Hurst, R. S.; Maklad, N.; Mather, R. J.; McLean, S.; Nedza, F. M.; O’Neill, B. T.; Peng, L.; Qian, W.; Rottas, M. M.; Sands, S. B.; Schmidt, A. W.; Shrikhande, A. V.; Spracklin, D. K.; Wong, D. F.; Zhang, A.; Zhang, L. Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel α7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models J. Med. Chem. 2010, 53, 1222-1237 10.1021/jm9015075
91. Dosa, P. I.; Amin, E. A. Tactical approaches to interconverting GPCR agonists and antagonists J. Med. Chem. 2016, 59, 810-840 10.1021/acs.jmedchem.5b00982
92. 4 receptor antagonists: application to the design of new potential single photon emission computed tomography tracers J. Med. Chem. 2012, 55, 9693-9707 10.1021/jm300943r
93. Reid, R. C.; Yau, M.-K.; Singh, R.; Hamidon, J. K.; Lim, J.; Stoermer, M. J.; Fairlie, D. P. Potent heterocyclic ligands for human complement C3a receptor J. Med. Chem. 2014, 57, 8459-8470 10.1021/jm500956p
94. Li, G.; Aschenbach, L. C.; Chen, J.; Cassidy, M. P.; Stevens, D. L.; Gabra, B. H.; Selley, D. E.; Dewey, W. L.; Westkaemper, R. B.; Zhang, Y. Design, synthesis, and biological evaluation of 6α-and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective antagonists J. Med. Chem. 2009, 52, 1416-1427 10.1021/jm801272c
95. Li, G.; Aschenbach, L. C.; Chen, J.; Cassidy, M. P.; Stevens, D. L.; Gabra, B. H.; Selley, D. E.; Dewey, W. L.; Westkaemper, R. B.; Zhang, Y. Corrections to design, synthesis, and biological evaluation of 6α-and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective antagonists J. Med. Chem. 2009, 52, 8057-8057 10.1021/jm9016224
96. Yekkirala, A. S.; Lunzer, M. M.; McCurdy, C. R.; Powers, M. D.; Kalyuzhny, A. E.; Roerig, S. C.; Portoghese, P. S. N-Naphthoyl-β-naltrexamine (NNTA), a highly selective and potent activator of μ/κ-opioid heteromers Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 5098-5103 10.1073/pnas.1016277108
97. Young, R. J. Physical properties in drug design Top. Med. Chem. 2015, 9, 1-68 10.1007/7355_2013_35
98. Walker, M. A. Improving solubility via structural modification Top. Med. Chem. 2015, 9, 69-106 10.1007/7355_2013_32
99. Liu, X.; Wright, M.; Hop, C. E. C. A. Rational use of plasma protein and tissue binding data in drug design J. Med. Chem. 2014, 57, 8238-8248 10.1021/jm5007935
100. Ward, K. W. Optimizing pharmacokinetic properties and attaining candidate selection Top. Med. Chem. 2014, 11, 73-96 10.1007/7355_2012_19
101. Spracklin, D. K.; Kalgutkar, A. S.; Nedderman, A. N. R. The role of biotransformation studies in reducing drug attrition Top. Med. Chem. 2014, 11, 97-138 10.1007/7355_2012_18
102. Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs; Di, L.; Kerns, E. H., Eds.; John Wiley & Sons: Hoboken, 2015.
103. Rankovic, Z. CNS drug design: balancing physicochemical properties for optimal brain exposure J. Med. Chem. 2015, 58, 2584-2608 10.1021/jm501535r
104. Gunaydin, H.; Weiss, M. M.; Sun, Y. De novo prediction of P-glycoprotein-mediated efflux liability for druglike compounds ACS Med. Chem. Lett. 2013, 4, 108-112 10.1021/ml300314h
105. Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry J. Med. Chem. 2010, 53, 2601-2611 10.1021/jm100087s
106. Scully, S. S.; Tang, A. J.; Lundh, M.; Mosher, C. M.; Perkins, K. M.; Wagner, B. K. Small-molecule inhibitors of cytokine-mediated STAT1 signal transduction in β-cells with improved aqueous solubility J. Med. Chem. 2013, 56, 4125-4129 10.1021/jm400397x
107. Traquandi, G.; Ciomei, M.; Ballinari, D.; Casale, E.; Colombo, N.; Croci, V.; Fiorentini, F.; Isacchi, A.; Longo, A.; Mercurio, C.; Panzeri, A.; Pastori, W.; Pevarello, P.; Volpi, D.; Roussel, P.; Vulpetti, A.; Brasca, M. G. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors J. Med. Chem. 2010, 53, 2171-2187 10.1021/jm901710h
108. Sugane, T.; Tobe, T.; Hamaguchi, W.; Shimada, I.; Maeno, K.; Miyata, J.; Suzuki, T.; Kimizuka, T.; Sakamoto, S.; Tsukamoto, S.-i. Atropisomeric 4-phenyl-4H-1,2,4-triazoles as selective glycine transporter 1 inhibitors J. Med. Chem. 2013, 56, 5744-5756 10.1021/jm400383w
109. Yokokawa, F.; Wang, G.; Chan, W. L.; Ang, S. H.; Wong, J.; Ma, I.; Rao, S. P. S.; Manjunatha, U.; Lakshminarayana, S. B.; Herve, M.; Kounde, C.; Tan, B. H.; Thayalan, P.; Ng, S. H.; Nanjundappa, M.; Ravindran, S.; Gee, P.; Tan, M.; Wei, L.; Goh, A.; Chen, P.-Y.; Lee, K. S.; Zhong, C.; Wagner, T.; Dix, I.; Chatterjee, A. K.; Pethe, K.; Kuhen, K.; Glynne, R.; Smith, P.; Bifani, P.; Jiricek, J. Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents ACS Med. Chem. Lett. 2013, 4, 451-455 10.1021/ml400071a
110. Kiselev, E.; DeGuire, S.; Morrell, A.; Agama, K.; Dexheimer, T. S.; Pommier, Y.; Cushman, M. 7-Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents J. Med. Chem. 2011, 54, 6106-6116 10.1021/jm200719v
111. Hong, S.-P.; Liu, K. G.; Ma, G.; Sabio, M.; Uberti, M. A.; Bacolod, M. D.; Peterson, J.; Zou, Z. Z.; Robichaud, A. J.; Doller, D. Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators J. Med. Chem. 2011, 54, 5070-5081 10.1021/jm200290z
112. Huang, H.; Degnan, A. P.; Balakrishnan, A.; Easton, A.; Gulianello, M.; Huang, Y.; Matchett, M.; Mattson, G.; Miller, R.; Santone, K. S.; Senapati, A.; Shields, E. E.; Sivarao, D. V.; Snyder, L. B.; Westphal, R.; Whiterock, V. J.; Yang, F.; Bronson, J. J.; Macor, J. E. Oxazolidinone-based allosteric modulators of mGluR5: defining molecular switches to create a pharmacological tool box Bioorg. Med. Chem. Lett. 2016, 26, 4165-4169 10.1016/j.bmcl.2016.07.065
113. 11C]MK-4232: The first positron emission tomography tracer for the calcitonin gene-related peptide receptor ACS Med. Chem. Lett. 2013, 4, 863-868 10.1021/ml400199p
114. Dzierba, C. D.; Sielecki, T. M.; Arvanitis, A. G.; Galka, A.; Johnson, T. L.; Takvorian, A. G.; Rafalski, M.; Kasireddy-Polam, P.; Vig, S.; Dasgupta, B.; Zhang, G.; Molski, T. F.; Wong, H.; Zaczek, R. C.; Lodge, N. J.; Combs, A. P.; Gilligan, P. J.; Trainor, G. L.; Bronson, J. J.; Macor, J. E. Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists Bioorg. Med. Chem. Lett. 2012, 22, 4986-4989 10.1016/j.bmcl.2012.06.034
115. Govek, S. P.; Nagasawa, J. Y.; Douglas, K. L.; Lai, A. G.; Kahraman, M.; Bonnefous, C.; Aparicio, A. M.; Darimont, B. D.; Grillot, K. L.; Joseph, J. D.; Kaufman, J. A.; Lee, K.-J.; Lu, N.; Moon, M. J.; Prudente, R. Y.; Sensintaffar, J.; Rix, P. J.; Hager, J. H.; Smith, N. D. Optimization of an indazole series of selective estrogen receptor degraders: tumor regression in a tamoxifen-resistant breast cancer xenograft Bioorg. Med. Chem. Lett. 2015, 25, 5163-5167 10.1016/j.bmcl.2015.09.074
116. Zheng, X.; Bauer, P.; Baumeister, T.; Buckmelter, A. J.; Caligiuri, M.; Clodfelter, K. H.; Han, B.; Ho, Y.-C.; Kley, N.; Lin, J.; Reynolds, D. J.; Sharma, G.; Smith, C. C.; Wang, Z.; Dragovich, P. S.; Oh, A.; Wang, W.; Zak, M.; Gunzner-Toste, J.; Zhao, G.; Yuen, P.-w.; Bair, K. W. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors J. Med. Chem. 2013, 56, 4921-4937 10.1021/jm400186h
117. Lingam, V. S. P.; Dahale, D. H.; Rathi, V. E.; Shingote, Y. B.; Thakur, R. R.; Mindhe, A. S.; Kummari, S.; Khairatkar-Joshi, N.; Bajpai, M.; Shah, D. M.; Sapalya, R. S.; Gullapalli, S.; Gupta, P. K.; Gudi, G. S.; Jadhav, S. B.; Pattem, R.; Thomas, A. Design, synthesis, and pharmacological evaluation of 5,6-disubstituted pyridin-2(1H)-one derivatives as phosphodiesterase 10A (PDE10A) antagonists J. Med. Chem. 2015, 58, 8292-8308 10.1021/acs.jmedchem.5b01240
118. Fukaya, T.; Ishiyama, T.; Baba, S.; Masumoto, S. Identification of a novel benzoxazolone derivative as a selective, orally active 18 kDa translocator protein (TSPO) ligand J. Med. Chem. 2013, 56, 8191-8195 10.1021/jm401325r
119. Doherty, E. M.; Fotsch, C.; Bannon, A. W.; Bo, Y.; Chen, N.; Dominguez, C.; Falsey, J.; Gavva, N. R.; Katon, J.; Nixey, T.; Ognyanov, V. I.; Pettus, L.; Rzasa, R. M.; Stec, M.; Surapaneni, S.; Tamir, R.; Zhu, J.; Treanor, J. J. S.; Norman, M. H. Novel vanilloid receptor-1 antagonists: 2. structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate J. Med. Chem. 2007, 50, 3515-3527 10.1021/jm070190p
120. Cid, J. M.; Tresadern, G.; Vega, J. A.; de Lucas, A. I.; Matesanz, E.; Iturrino, L.; Linares, M. L.; Garcia, A.; Andrés, J.; Macdonald, G. J.; Oehlrich, D.; Lavreysen, H.; Megens, A.; Ahnaou, A.; Drinkenburg, W.; Mackie, C.; Pype, S.; Gallacher, D.; Trabanco, A. A. Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor J. Med. Chem. 2012, 55, 8770-8789 10.1021/jm3010724
121. Cioffi, C. L.; Dobri, N.; Freeman, E. E.; Conlon, M. P.; Chen, P.; Stafford, D. G.; Schwarz, D. M. C.; Golden, K. C.; Zhu, L.; Kitchen, D. B.; Barnes, K. D.; Racz, B.; Qin, Q.; Michelotti, E.; Cywin, C. L.; Martin, W. H.; Pearson, P. G.; Johnson, G.; Petrukhin, K. Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease J. Med. Chem. 2014, 57, 7731-7757 10.1021/jm5010013
122. Johnson, D. S.; Stiff, C.; Lazerwith, S. E.; Kesten, S. R.; Fay, L. K.; Morris, M.; Beidler, D.; Liimatta, M. B.; Smith, S. E.; Dudley, D. T.; Sadagopan, N.; Bhattachar, S. N.; Kesten, S. J.; Nomanbhoy, T. K.; Cravatt, B. F.; Ahn, K. Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor ACS Med. Chem. Lett. 2011, 2, 91-96 10.1021/ml100190t
123. Savall, B. M.; Wu, D.; De Angelis, M.; Carruthers, N. I.; Ao, H.; Wang, Q.; Lord, B.; Bhattacharya, A.; Letavic, M. A. Synthesis, SAR, and pharmacological characterization of brain penetrant P2X7 receptor antagonists ACS Med. Chem. Lett. 2015, 6, 671-676 10.1021/acsmedchemlett.5b00089
124. Safina, B. S.; Baker, S.; Baumgardner, M.; Blaney, P. M.; Chan, B. K.; Chen, Y.-H.; Cartwright, M. W.; Castanedo, G.; Chabot, C.; Cheguillaume, A. J.; Goldsmith, P.; Goldstein, D. M.; Goyal, B.; Hancox, T.; Handa, R. K.; Iyer, P. S.; Kaur, J.; Kondru, R.; Kenny, J. R.; Krintel, S. L.; Li, J.; Lesnick, J.; Lucas, M. C.; Lewis, C.; Mukadam, S.; Murray, J.; Nadin, A. J.; Nonomiya, J.; Padilla, F.; Palmer, W. S.; Pang, J.; Pegg, N.; Price, S.; Reif, K.; Salphati, L.; Savy, P. A.; Seward, E. M.; Shuttleworth, S.; Sohal, S.; Sweeney, Z. K.; Tay, S.; Tivitmahaisoon, P.; Waszkowycz, B.; Wei, B.; Yue, Q.; Zhang, C.; Sutherlin, D. P. Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition J. Med. Chem. 2012, 55, 5887-5900 10.1021/jm3003747
125. Barsanti, P. A.; Pan, Y.; Lu, Y.; Jain, R.; Cox, M.; Aversa, R. J.; Dillon, M. P.; Elling, R.; Hu, C.; Jin, X.; Knapp, M.; Lan, J.; Ramurthy, S.; Rudewicz, P.; Setti, L.; Subramanian, S.; Mathur, M.; Taricani, L.; Thomas, G.; Xiao, L.; Yue, Q. Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors ACS Med. Chem. Lett. 2015, 6, 42-46 10.1021/ml500352s
126. McMinn, D. L.; Rew, Y.; Sudom, A.; Caille, S.; DeGraffenreid, M.; He, X.; Hungate, R.; Jiang, B.; Jaen, J.; Julian, L. D.; Kaizerman, J.; Novak, P.; Sun, D.; Tu, H.; Ursu, S.; Walker, N. P. C.; Yan, X.; Ye, Q.; Wang, Z.; Powers, J. P. Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 1446-1450 10.1016/j.bmcl.2009.01.026
127. Sun, W.; Maletic, M.; Mundt, S. S.; Shah, K.; Zokian, H.; Lyons, K.; Waddell, S. T.; Balkovec, J. Substituted phenyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 Bioorg. Med. Chem. Lett. 2011, 21, 2141-2145 10.1016/j.bmcl.2011.01.125
128. v1.7 antagonists: hit-to-lead identification and SAR Bioorg. Med. Chem. Lett. 2012, 22, 2033-2042 10.1016/j.bmcl.2012.01.023
129. Deng, Q.; Lim, Y.-H.; Anand, R.; Yu, Y.; Kim, J.-h.; Zhou, W.; Zheng, J.; Tempest, P.; Levorse, D.; Zhang, X.; Greene, S.; Mullins, D.; Culberson, C.; Sherborne, B.; Parker, E. M.; Stamford, A.; Ali, A. Use of molecular modeling aided design to dial out hERG liability in adenosine A2A receptor antagonists Bioorg. Med. Chem. Lett. 2015, 25, 2958-2962 10.1016/j.bmcl.2015.05.036
130. Zanaletti, R.; Bettinetti, L.; Castaldo, C.; Ceccarelli, I.; Cocconcelli, G.; Comery, T. A.; Dunlop, J.; Genesio, E.; Ghiron, C.; Haydar, S. N.; Jow, F.; Maccari, L.; Micco, I.; Nencini, A.; Pratelli, C.; Scali, C.; Turlizzi, E.; Valacchi, M. N-[5-(5-Fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): a medicinal chemistry effort toward an α7 nicotinic acetylcholine receptor agonist preclinical candidate J. Med. Chem. 2012, 55, 10277-10281 10.1021/jm3013568
131. Shamovsky, I.; Ripa, L.; Börjesson, L.; Mee, C.; Nordén, B.; Hansen, P.; Hasselgren, C.; O’Donovan, M.; Sjö, P. Explanation for main features of structure-genotoxicity relationships of aromatic amines by theoretical studies of their activation pathways in CYP1A2 J. Am. Chem. Soc. 2011, 133, 16168-16185 10.1021/ja206427u
132. McCarren, P.; Bebernitz, G. R.; Gedeck, P.; Glowienke, S.; Grondine, M. S.; Kirman, L. C.; Klickstein, J.; Schuster, H. F.; Whitehead, L. Avoidance of the Ames test liability for aryl-amines via computation Bioorg. Med. Chem. 2011, 19, 3173-3182 10.1016/j.bmc.2011.03.066
133. Boldron, C.; Besse, A.; Bordes, M.-F.; Tissandié, S.; Yvon, X.; Gau, B.; Badorc, A.; Rousseaux, T.; Barré, G.; Meneyrol, J.; Zech, G.; Nazare, M.; Fossey, V.; Pflieger, A.-M.; Bonnet-Lignon, S.; Millet, L.; Briot, C.; Dol, F.; Hérault, J.-P.; Savi, P.; Lassalle, G.; Delesque, N.; Herbert, J.-M.; Bono, F. N-[6-(4-Butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist J. Med. Chem. 2014, 57, 7293-7316 10.1021/jm500588w
134. Beaulieu, P. L.; Bolger, G.; Duplessis, M.; Gagnon, A.; Garneau, M.; Stammers, T.; Kukolj, G.; Duan, J. Aza follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 1: mitigating the genotoxic liability of an aniline metabolite Bioorg. Med. Chem. Lett. 2015, 25, 1135-1139 10.1016/j.bmcl.2014.12.028
135. Li, J. J.; Nahra, J.; Johnson, A. R.; Bunker, A.; O’Brien, P.; Yue, W.-S.; Ortwine, D. F.; Man, C.-F.; Baragi, V.; Kilgore, K.; Dyer, R. D.; Han, H.-K. Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis J. Med. Chem. 2008, 51, 835-841 10.1021/jm701274v
136. González Cabrera, D. G.; Douelle, F.; Younis, Y.; Feng, T.-S.; Le Manach, C.; Nchinda, A. T.; Street, L. J.; Scheurer, C.; Kamber, J.; White, K. L.; Montagnat, O. D.; Ryan, E.; Katneni, K.; Zabiulla, K. M.; Joseph, J. T.; Bashyam, S.; Waterson, D.; Witty, M. J.; Charman, S. A.; Wittlin, S.; Chibale, K. Structure-activity relationship studies of orally active antimalarial 3,5-substituted 2-aminopyridines J. Med. Chem. 2012, 55, 11022-11030 10.1021/jm301476b
137. Zou, B.; Chan, W. L.; Ding, M.; Leong, S. Y.; Nilar, S.; Seah, P. G.; Liu, W.; Karuna, R.; Blasco, F.; Yip, A.; Chao, A.; Susila, A.; Dong, H.; Wang, Q. Y.; Xu, H. Y.; Chan, K.; Wan, K. F.; Gu, F.; Diagana, T. T.; Wagner, T.; Dix, I.; Shi, P.-Y.; Smith, P. W. Lead optimization of spiropyrazolopyridones: a new and potent class of dengue virus inhibitors ACS Med. Chem. Lett. 2015, 6, 344-348 10.1021/ml500521r
138. Horne, D. B.; Tamayo, N. A.; Bartberger, M. D.; Bo, Y.; Clarine, J.; Davis, C. D.; Gore, V. K.; Kaller, M. R.; Lehto, S. G.; Ma, V. V.; Nishimura, N.; Nguyen, T. T.; Tang, P.; Wang, W.; Youngblood, B. D.; Zhang, M.; Gavva, N. R.; Monenschein, H.; Norman, M. H. Optimization of potency and pharmacokinetic properties of tetrahydroisoquinoline transient receptor potential melastatin 8 (TRPM8) antagonists J. Med. Chem. 2014, 57, 2989-3004 10.1021/jm401955h
139. Shin, Y.; Suchomel, J.; Cardozo, M.; Duquette, J.; He, X.; Henne, K.; Hu, Y.-L.; Kelly, R. C.; McCarter, J.; McGee, L. R.; Medina, J. C.; Metz, D.; San Miguel, T.; Mohn, D.; Tran, T.; Vissinga, C.; Wong, S.; Wannberg, S.; Whittington, D. A.; Whoriskey, J.; Yu, G.; Zalameda, L.; Zhang, X.; Cushing, T. D. Discovery, optimization, and in vivo evaluation of benzimidazole derivatives AM-8508 and AM-9635 as potent and selective PI3Kδ inhibitors J. Med. Chem. 2016, 59, 431-447 10.1021/acs.jmedchem.5b01651